Abstract
Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction. Platelets play a crucial role in thrombosis and haemostasis, which can be either beneficial or deleterious, depending on the circumstances. Platelet hyperreactivity is a multifactor process depending on genetic polymorphism, pathological state and lifestyle; it contributes to the activation of the thrombotic cascade. Under pathophysiological conditions platelets activation plays a critical role in arterial thrombosis including platelets aggregation, the basis of destabilization of coronary plaque. Despite the benefits observed in outcome when primary angioplasty is compared with thrombolysis for the treatment of acute myocardial infarction there is still some room for improvement; unfortunately the restoration of an “optimal” epicardial flow is not always related to an “optimal” myocardial reperfusion. In the recent, past several studies have shown significant benefits with the administration of glycoprotein IIb/IIIa inhibitors. Thus, the aim of the present review is to perform an update on factors associated with platelets hyperactivity and on adjunctive glycoprotein IIb – IIIa inhibitors in primary angioplasty.
Keywords: STEMI, PCI, GP IIb/IIIa, Abciximab, Tifofiban, Eptifibatide, no reflow phenomenon, microvascular disease, sistolic dysfunction, coronary thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention
Volume: 9 Issue: 2
Author(s): Andrea Rognoni, Alessandro Lupi, Gioel Gabrio Secco, Chiara Cavallino, Mara Sansa, Maurizio Lazzero and Angelo Sante Bongo
Affiliation:
Keywords: STEMI, PCI, GP IIb/IIIa, Abciximab, Tifofiban, Eptifibatide, no reflow phenomenon, microvascular disease, sistolic dysfunction, coronary thrombosis
Abstract: Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction. Platelets play a crucial role in thrombosis and haemostasis, which can be either beneficial or deleterious, depending on the circumstances. Platelet hyperreactivity is a multifactor process depending on genetic polymorphism, pathological state and lifestyle; it contributes to the activation of the thrombotic cascade. Under pathophysiological conditions platelets activation plays a critical role in arterial thrombosis including platelets aggregation, the basis of destabilization of coronary plaque. Despite the benefits observed in outcome when primary angioplasty is compared with thrombolysis for the treatment of acute myocardial infarction there is still some room for improvement; unfortunately the restoration of an “optimal” epicardial flow is not always related to an “optimal” myocardial reperfusion. In the recent, past several studies have shown significant benefits with the administration of glycoprotein IIb/IIIa inhibitors. Thus, the aim of the present review is to perform an update on factors associated with platelets hyperactivity and on adjunctive glycoprotein IIb – IIIa inhibitors in primary angioplasty.
Export Options
About this article
Cite this article as:
Rognoni Andrea, Lupi Alessandro, Gabrio Secco Gioel, Cavallino Chiara, Sansa Mara, Lazzero Maurizio and Sante Bongo Angelo, Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention, Cardiovascular & Hematological Agents in Medicinal Chemistry 2011; 9 (2) . https://dx.doi.org/10.2174/187152511796196524
DOI https://dx.doi.org/10.2174/187152511796196524 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Options to Treat Hypertriglyceridaemia
Current Drug Targets Secondary Prevention of Ischemic Stroke
Current Drug Targets Hypertension and Aortic Stenosis: A Review
Current Hypertension Reviews Identifying Multiple-target Ligands via Computational Chemogenomics Approaches
Current Topics in Medicinal Chemistry Domino Liver Transplantation: Where are we Now?
Reviews on Recent Clinical Trials Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) Translational Application of Combining Magnetic Resonance Imaging and Biomechanical Analysis in Carotid Plaque Vulnerability Assessment
Recent Patents on Medical Imaging Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Comparison of High-Sensitive CRP, RDW, PLR and NLR between Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Failure
Current Respiratory Medicine Reviews The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) The Efficacy of Psychological Therapies for Specific Phobias in Adults and Some Unanswered Questions
Current Psychiatry Reviews Editorial (Thematic Issue: Alcoholic Liver Disease: From Bench to Bedside)
Reviews on Recent Clinical Trials Update on the Molecular Genetic Studies of Behcets Disease
Current Rheumatology Reviews Takotsubo-Like Left Ventricular Dysfunction in an HIV-Infected Patient
Current HIV Research Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Natural Antioxidants in Wheat Sprout Extracts
Current Organic Chemistry Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Comparison between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease
Current Drug Metabolism HCN Pacemaker Channels and Pain: A Drug Discovery Perspective
Current Pharmaceutical Design